Grufity logoGrufity logo

ADPT

8.14USD+0.02(+0.25%)Market Closed

Adaptive Biotechnologies Corp

Market Summary

USD8.14+0.02Market Closed
0.25%

ADPT Alerts

ADPT Stock Price

RSI Chart

Valuation

Market Cap

1.1B

Price/Earnings

-4.68

Price/Sales

6.81

Price/Cashflow

-5.21

MarketCap/EBT

-4.37

Price/Sales

Profitability

EBT Margin

-129.82%

Return on Equity

-44.78%

Return on Assets

-28.78%

Fundamentals

Revenue

Revenue (TTM)

159.7M

Revenue Y/Y

13.39%

Revenue Q/Q

13.05%

Earnings

Earnings (TTM)

-232.1M

Earnings Y/Y

-5.57%

Earnings Q/Q

17.04%

Price Action

52 Week Range

5.9630.51
(Low)(High)

Last 7 days

-1.5%

Last 30 days

7.0%

Last 90 days

-5.9%

Trailing 12 Months

-71.0%

Financial Health

Current Ratio

3.93

Investor Care

Shares Dilution (1Y)

1.50%

Diluted EPS (TTM)

-1.65

Peers (Alternatives to Adaptive BioTech)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
41.1B
6.7B
9.75% 0.62%
30.93
6.17
8.42% 34.14%
36.7B
4.7B
-6.91% -41.34%
-1.9K
7.81
9.79% -558.28%
28.5B
3.9B
13.87% -3.79%
34.68
7.36
7.75% 11.02%
11.6B
1.1B
11.81% -30.16%
42.59
10.48
13.51% 65.31%
10.1B
801.3M
-5.69% -39.99%
63.34
12.97
35.20% 39.92%
MID-CAP
SMALL-CAP
2.0B
137.0M
11.47% -58.32%
-9.53
14.05
12.61% -709.53%
1.1B
159.7M
6.96% -71.05%
-4.68
6.81
19.67% -35.56%
661.5M
23.3M
-10.53% -49.00%
-6.25
28.36
76.56% -106.44%
488.2M
135.3M
-44.10% -85.90%
-3.51
3.42
-2.59% -32.75%
413.2M
110.0M
6.62% -72.35%
-5.25
3.72
3.37% -106.72%
372.0M
132.7M
-11.27% -86.24%
-19.64
2.76
31.03% -107.73%
109.5M
118.0M
-13.69% -67.10%
-29.97
0.91
0.97% -269.58%
105.9M
68.8M
9.68% -65.38%
-3.75
1.53
5.65% 26.86%
95.7M
51.6M
-0.85% -23.94%
238.75
1.86
20.72% 150.31%

Financials for Adaptive BioTech

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue3.3%160155154147133
  S&GA Expenses1.1%102101958777
  R&D Expenses-0.5%146146142143138
Earnings Before Taxes--207.30
Net Income-1.2%-232.12-229.37-207.28-190.42-171.23
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-6.0%8078589239931,033
  Current Assets4.6%439419403467644
    Cash Equivalents-33.4%76115139122184
  Inventory-10.6%1921191819
  Net PPE1.0%8786858875
  Goodwill0%119119119119119
Liabilities-5.5%288305319341340
  Current Liabilities-3.1%111115114122117
Shareholder's Equity-6.3%518553604652693
  Retained Earnings-6.7%-833.67-781.63-718.89-657.46-601.55
  Additional Paid-In Capital1.4%1,3581,3401,3241,3091,295
Accumulated Depreciation-36----
Shares Outstanding0.4%143142141141141
Minority Interest-76.0%00000
Float-3,951----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-5.0%-208.79-198.93-192.73-178.74-182.46
  Share Based Compensation6.2%5148433933
Cashflow From Investing-29.3%88125181-226.05-302.03
Cashflow From Financing-15.3%13152730303

Risks

What is the probability of a big loss on ADPT?

98.3%


Probability that Adaptive BioTech stock will be more than 20% underwater in next one year

91.7%


Probability that Adaptive BioTech stock will be more than 30% underwater in next one year.

90%


Probability that Adaptive BioTech stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ADPT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Adaptive BioTech was unfortunately bought at previous high price.

Returns

Cumulative Returns on ADPT

-33.1%


3-Year Cumulative Returns

Which funds bought or sold ADPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
CVA Family Office, LLC
-
-
-
3,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-143,000
923,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
ADDED
966.41
79,000
88,000
-%
2022-11-15
Neuberger Berman Group LLC
ADDED
11.4
-82,000
4,113,000
-%
2022-11-15
Almanack Investment Partners, LLC.
NEW
-
2,000
2,000
-%
2022-11-15
ALLIANCEBERNSTEIN L.P.
REDUCED
-4.77
-182,000
941,000
-%
2022-11-15
AVENIR CORP
REDUCED
-43.35
-220,000
218,000
0.02%
2022-11-15
Balyasny Asset Management LLC
SOLD OFF
-100
-5,005,000
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
-12,000
88,000
-%
2022-11-15
HARBOUR INVESTMENTS, INC.
UNCHANGED
-
-
1,000
-%

1–10 of 47

Latest Funds Activity

Are funds buying ADPT calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ADPT

Adaptive BioTech News

Stockhouse

2022-11-21 | NDAQ:ADPT | Press Release | Adaptive Biotechnologies Corporation.7 days ago

ADPT Fair Value

Recent SEC filings of Adaptive BioTech

View All Filings
Date Filed Form Type Document
Nov 17, 2022
4/A
Insider Trading
Nov 17, 2022
4
Insider Trading
Nov 03, 2022
8-K
Current Report
Nov 03, 2022
10-Q
Quarterly Report
Nov 01, 2022
4
Insider Trading
Oct 11, 2022
4
Insider Trading
Sep 12, 2022
SC 13G/A
Major Ownership Report
Sep 12, 2022
8-K
Current Report

Latest Insider Trading transactions for ADPT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-16
PISKEL KYLE
SOLD
-8,506.33
8.87
-959
Principal Accounting Officer
2022-11-16
PISKEL KYLE
SOLD
-2,723.09
8.87
-307
Principal Accounting Officer
2022-11-01
SOOD NITIN
SOLD
-248,528
8
-31,066
Chief Commercial Officer, MRD
2022-10-10
ADAMS R MARK
SOLD
-16,284.9
7.13
-2,284
Chief Operating Officer
2022-10-07
ADAMS R MARK
SOLD
-6,400.01
7.61
-841
Chief Operating Officer
2022-08-05
SOOD NITIN
SOLD
-192,589
10.98
-17,540
Chief Commercial Officer, MRD
2022-07-08
ADAMS R MARK
SOLD
-24,081
10.47
-2,300
Chief Operating Officer
2022-07-07
ADAMS R MARK
SOLD
-7,862.25
9.53
-825
Chief Operating Officer
2022-06-01
PETERSON TYCHO
ACQUIRED
-
-
374,688
Chief Financial Officer
2022-04-07
ADAMS R MARK
SOLD
-10,944.3
13.17
-831
Chief Operating Officer

1–10 of 50

Chad Robins
860
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

ADPT Income Statement

2022-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue$ 47,830$ 39,467$ 130,110$ 116,414
Operating expenses    
Cost of revenue14,90714,18941,32034,945
Research and development35,65836,072110,534107,644
Sales and marketing21,51324,94971,88768,769
General and administrative20,75520,15466,09951,156
Amortization of intangible assets4284281,2701,270
Total operating expenses93,26195,792291,110263,784
Loss from operations(45,431)(56,325)(161,000)(147,370)
Interest and other income, net7653271,4541,429
Interest expense(653) (653) 
Net loss(45,319)(55,998)(160,199)(145,941)
Add: Net loss attributable to noncontrolling interest389513695
Net loss attributable to Adaptive Biotechnologies Corporation$ (45,281)$ (55,903)$ (160,063)$ (145,846)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic$ (0.32)$ (0.40)$ (1.12)$ (1.04)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic142,928,654140,833,564142,334,342140,060,379
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted$ (0.32)$ (0.40)$ (1.12)$ (1.04)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted142,928,654140,833,564142,334,342140,060,379

ADPT Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and cash equivalents$ 217,552,000$ 139,065,000
Short-term marketable securities (amortized cost of $295,689 and $214,115, respectively)290,527,000213,996,000
Accounts receivable, net26,549,00017,409,000
Inventory17,345,00019,263,000
Prepaid expenses and other current assets12,407,00013,015,000
Total current assets564,380,000402,748,000
Long-term assets  
Property and equipment, net86,662,00085,262,000
Operating lease right-of-use assets82,605,00087,678,000
Long-term marketable securities (amortized cost of $20,507 and $218,163, respectively)19,698,000217,145,000
Restricted cash2,433,0002,138,000
Intangible assets, net7,256,0008,526,000
Goodwill118,972,000118,972,000
Other assets2,202,000875,000
Total assets884,208,000923,344,000
Current liabilities  
Accounts payable4,163,0003,307,000
Accrued liabilities10,702,0009,343,000
Accrued compensation and benefits12,733,00015,642,000
Current portion of operating lease liabilities8,528,0005,055,000
Current portion of deferred revenue67,892,00080,460,000
Total current liabilities104,018,000113,807,000
Long-term liabilities  
Operating lease liabilities, less current portion100,521,000106,685,000
Deferred revenue, less current portion67,300,00098,750,000
Revenue interest liability, net124,555,000 
Total liabilities396,394,000319,242,000
Commitments and contingencies (Note 9)
Shareholders’ equity  
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 2021
Common stock: $0.0001 par value, 340,000,000 shares authorized at September 30, 2022 and December 31, 2021; 142,987,127 and 141,393,865 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively14,00014,000
Additional paid-in capital1,372,751,0001,324,006,000
Accumulated other comprehensive loss(5,971,000)(1,137,000)
Accumulated deficit(878,954,000)(718,891,000)
Total Adaptive Biotechnologies Corporation shareholders’ equity487,840,000603,992,000
Noncontrolling interest(26,000)110,000
Total shareholders’ equity487,814,000604,102,000
Total liabilities and shareholders’ equity$ 884,208,000$ 923,344,000